Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $52.83 and last traded at $52.83, with a volume of 0 shares changing hands. The stock had previously closed at $52.83.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright upgraded Basilea Pharmaceutica to a “strong-buy” rating in a research report on Monday, September 23rd.
Check Out Our Latest Analysis on Basilea Pharmaceutica
Basilea Pharmaceutica Stock Performance
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.
Further Reading
- Five stocks we like better than Basilea Pharmaceutica
- Canadian Penny Stocks: Can They Make You Rich?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Options Trading – Understanding Strike Price
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Insider Trades May Not Tell You What You Think
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
